This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Contraindications

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • should not be used in patients with evidence of previous MI
  • relatively contraindicated in patients with heart failure, cardiomyopathy, haemodynamically significant valvular heart disease (1)
  • hepatic or renal impairment can lead to a reduction in elimination of flecainide
  • flecainide may lead to a depression in myocardial function and may cause heart failure

Notes:

  • the BNF states that heart failure and haemodynamically significant valvular heart disease are both contraindications to the use of flecainide
  • flecainide has also been associated with proarrhythmia in some children, and there are reports of an increased incidence of sudden death among patients with atrial flutter, structural heart disease and cardiomyopathies (3)

Reference:

  1. Prescribers' Journal (1999), 39 (4), 222-26.
  2. BNF 2.3.2
  3. Kugler JD.Radiofrequency catheter ablation for supraventricular tachycardia: should it be used in infants and small children?. Circulation 1994;90:639–641
  4. Fish FA et al. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. J Am Coll Cardiol 1991;18:356–365.

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.